Evidence map›Paper›PMID 35386917›Full record

ReviewFrontiers in medicine2022

Iron Overload in Chronic Kidney Disease: Less Ferritin, More T2

Abdulqadir J Nashwan, Mohamed A Yassin, Mohamed Izham Mohamed Ibrahim, Hanan F Abdul Rahim, Mujahed Shraim

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Safety and Efficacy of Iron Chelators in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.Hemodialysis international. International Symposium on Home Hemodialysis · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Abdulqadir J NashwanDepartment of Nursing, Hazm Mebaireek General Hospital, Hamad Medical Corporation, Doha, Qatar.
Mohamed A YassinHematology and Oncology, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Mohamed Izham Mohamed IbrahimCollege of Pharmacy, QU Health, Qatar University, Doha, Qatar.
Hanan F Abdul RahimDepartment of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
Mujahed ShraimDepartment of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
Qatar University · QAHamad General Hospital · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To date, there is no consensus on the most reliable marker of iron status in patients with chronic kidney disease (CKD). Serum ferritin is used routinely, although it may be a misleading marker for iron overload. The success of T2

Indexed as

chronic kidney diseaseiron overloadliver iron concentration (LIC)serum ferritinT2*MRI

Identifiers

PMID35386917
PMCPMC8977522
OpenAlexW4226338155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.